S. 652In Committee
Protecting Patients from Deceptive Drug Ads Act
Plain-English overview
What this bill does
Establishes civil penalties, disclosure rules, and reporting requirements for deceptive prescription drug promotion on social media and through telehealth
Key points
- Establish civil penalties
- Require ad risk disclosures
- Require payment reporting
- Authorize FDA market surveillance
Current status
Where it stands
Status
In Committee
Latest action
2025-02-20 — Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S1129-1130)
Related context
Topics and policy areas
Select a topic to continue exploring related legislation, members, and committees.
Discovery signals
About these signals
Impact and Momentum are relative discovery aids calculated by Legislation Lemur. They help you scan the congressional record; they are not predictions, endorsements, ideological ratings, or measures of policy importance.
Impact ScoreOverall observed legislative footprint and accumulated activity.
MomentumHow recently active or changing the bill appears in available data.